Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Gastrointestinal (GI) cancer, including gastric cancer (GC), colorectal cancer (CRC), and esophageal squamous cell carcinoma (ESCC), is the most common malignancy worldwide. To identify genes that encode transmembrane proteins present in GI cancer, Escherichia coli ampicillin secretion trap libraries were generated from MKN-74 GC cells, and BST2 was identified as overexpressed in GC. This study analyzed the expression and function of the BST2 gene in human GI cancers and examined the relationship between bone marrow stromal antigen-2 (BST-2) expression and GI patient clinicopathologic characteristics.

Methods

Expression and distribution of BST-2 protein was analyzed by immunohistochemistry in 180 GC cases, 140 CRC cases, and 132 ESCC cases. Cell growth was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

Results

Immunohistochemical analysis of BST-2 in GC tissues showed that 65 (36 %) of 180 GC cases were positive for BST-2. Uni- and multivariate analyses demonstrated that BST-2 expression is an independent prognostic classifier of GC patients. Immunohistochemical analysis showed that 46 % of 140 CRC cases and 27 % of 132 ESCC cases were positive for BST-2. In ESCC, BST-2 expression was an independent prognostic predictor for survival. The growth of BST2 small interfering RNA (siRNA)-transfected GC cells was significantly slower than the growth of negative control siRNA-transfected GC cells. The levels of phosphorylated epidermal growth factor receptor, extracellular signal-regulated kinase, and Akt were lower in BST2 siRNA-transfected GC cells than in control cells.

Conclusions

The results suggest that BST-2 is involved in tumor progression and serves as an independent prognostic classifier for patients with GC. Because BST-2 is expressed on the cell membrane, BST-2 could be a therapeutic target for GC, CRC, and ESCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 2004;95:385–92.

    Article  CAS  PubMed  Google Scholar 

  2. Oue N, Sentani K, Sakamoto N, Yasui W. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. Cancer Sci. 2015;106:951–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2-based biology in 1006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17:34–42.

    Article  CAS  PubMed  Google Scholar 

  4. Van Loon K, Venook AP. Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol. 2011;23:403–9.

    Article  PubMed  Google Scholar 

  5. Ferguson DA, Muenster MR, Zang Q, et al. Selective identification of secreted and transmembrane breast cancer markers using Escherichia coli ampicillin secretion trap. Cancer Res. 2005;65:8209–17.

    Article  CAS  PubMed  Google Scholar 

  6. Anami K, Oue N, Noguchi T, et al. Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: expression of DSC2 in gastric cancer with intestinal phenotype. J Pathol. 2010;221:275–84.

    Article  CAS  PubMed  Google Scholar 

  7. Anami K, Oue N, Noguchi T, et al. TSPAN8, identified by Escherichia coli ampicillin secretion trap, is associated with cell growth and invasion in gastric cancer. Gastric Cancer (in press).

  8. Oo HZ, Sentani K, Sakamoto N, et al. Identification of novel transmembrane proteins in scirrhous-type gastric cancer by the Escherichia coli ampicillin secretion trap (CAST) method: TM9SF3 participates in tumor invasion and serves as a prognostic factor. Pathobiology. 2014;81:138–48.

    Article  CAS  PubMed  Google Scholar 

  9. Oo HZ, Sentani K, Sakamoto N, et al. Overexpression of ZDHHC14 promotes migration and invasion of scirrhous type gastric cancer. Oncol Rep. 2014;32:403–10.

    CAS  PubMed  Google Scholar 

  10. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic. 2003;4:694–709.

    Article  CAS  PubMed  Google Scholar 

  11. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 1994;84:1922–30.

    CAS  PubMed  Google Scholar 

  12. Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood. 1997;90:3179–86.

    CAS  PubMed  Google Scholar 

  13. Walter-Yohrling J, Cao X, Callahan M, et al. Identification of genes expressed in malignant cells that promote invasion. Cancer Res. 2003;63:8939–47.

    CAS  PubMed  Google Scholar 

  14. Cai D, Cao J, Li Z, et al. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer. 2009;9:102.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Yokoyama T, Enomoto T, Serada S, et al. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Int J Cancer. 2013;132:472–84.

    Article  CAS  PubMed  Google Scholar 

  16. Wang W, Nishioka Y, Ozaki S, et al. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother. 2009;58:967–76.

    Article  PubMed  Google Scholar 

  17. Sobin LH, Wittekind CH, eds. TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002, pp 65–8.

    Google Scholar 

  18. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.

    CAS  PubMed  Google Scholar 

  19. Oue N, Noguchi T, Anami K, et al. Cytokeratin 7 is a predictive marker for survival in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:1902–10.

    Article  PubMed  Google Scholar 

  20. Johnson AH, Frierson HF, Zaika A, et al. Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am J Pathol. 2005;167:577–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301–11.

    Article  CAS  PubMed  Google Scholar 

  22. Sayeed A, Luciani-Torres G, Meng Z, Bennington JL, Moore DH, Dairkee SH. Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells. PLoS One. 2013;8:e67191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther. 2005;4:151–68.

    CAS  PubMed  Google Scholar 

  24. Staudinger M, Glorius P, Burger R, et al. The novel immunotoxin HM1.24-ETA’ induces apoptosis in multiple myeloma cells. Blood Cancer J. 2014;4:e219.

    CAS  Google Scholar 

  25. Takeuchi K, Ito F. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J. 2010;277:316–26.

    Article  CAS  PubMed  Google Scholar 

  26. Harada T, Ozaki S. Targeted therapy for HM1.24 (CD317) on multiple myeloma cells. Biomed Res Int. 2014;2014:965384.

Download references

Acknowledgment

This work was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and from the Ministry of Health, Labour, and Welfare of Japan.

Conflict of interest

There are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan

    Shoichiro Mukai MD, Naohide Oue MD, PhD, Risa Mukai MD, Yoshiko Tatsumoto PhD, Naoya Sakamoto MD, PhD, Kazuhiro Sentani MD, PhD & Wataru Yasui MD, PhD

  2. Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan

    Shoichiro Mukai MD, Kazuaki Tanabe MD, PhD, Hiroyuki Egi MD, PhD, Takao Hinoi MD, PhD & Hideki Ohdan MD, PhD

  3. Department of Surgery, Yokohama City University, Yokohama, Japan

    Takashi Oshima MD, PhD

Authors
  1. Shoichiro Mukai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naohide Oue MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Oshima MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Risa Mukai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiko Tatsumoto PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoya Sakamoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuhiro Sentani MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuaki Tanabe MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroyuki Egi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takao Hinoi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hideki Ohdan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wataru Yasui MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naohide Oue MD, PhD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 4842 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mukai, S., Oue, N., Oshima, T. et al. Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer. Ann Surg Oncol 24, 594–602 (2017). https://doi.org/10.1245/s10434-016-5100-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5100-z

Keywords

Search

Navigation